Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer
Sponsor: Anglo Celtic Cooperative Oncology Group
Listed as NCT00030758, this PHASE4 trial focuses on Breast Cancer and Neutropenia and remains ongoing. Sponsored by Anglo Celtic Cooperative Oncology Group, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Oct 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anglo Celtic Cooperative Oncology Group
- Scottish Cancer Therapy Network
For direct contact, visit the study record on ClinicalTrials.gov .